Ceftibuten (CTB) 400 mg once daily for 5 days was compared at random to co-amoxiclav (250 mg amoxicillin and 125 mg clavulanic acid) or CMC thrice daily for 5-10 days. A total of 80 adult patients with informed conscent were entered into this study for clinical and bacteriological efficacy assessment. From 40 patients in the CTB group 22 could be analysed (positive significant urinary mid-stream bacteriuria) and compared to 20 patients fulfilling same criteria in CMC group. The overall symptoms cleared in most of the patients on the second day of treatment. Observed failures in both groups were due to pre-exiting pathology.  It may be conducted that ceftibuten with its simple dosing schedule seems to be an excellent alternative treatment regimen matching up to modern antimicrobial therapy for community acquired urinary tract infections.